Risk of Hepatocellular Carcinoma After Hepatitis C Virus Cure

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2022 Feb 7

PMID 35125821

Authors

Maria Alejandra Luna-Cuadros

Hao-Wei Chen

Hira Hanif

Mukarram Jamat Ali

Muzammil Muhammad Khan

Daryl Tan-Yeung Lau

Affiliations

Soon will be listed here.

Abstract

Hepatitis C virus (HCV) is a significant cause of hepatocellular carcinoma (HCC). The direct-acting antivirals marked a new era of HCV therapy and are associated with greater than 95% cure rate. Successful treatment of chronic hepatitis C greatly reduces the risk of HCC. A proportion of patients, especially those with pre-existing cirrhosis, remain at risk for HCC despite sustained virologic response (SVR). Diabetes mellitus, hepatic steatosis, alcohol consumption and lack of fibrosis regression are associated with risks of HCC after HCV cure. Noninvasive modalities such as aspartate aminotransferase to platelet ratio index and fibrosis-4 index and transient elastography have been used to monitor hepatic fibrosis. More recently, various fibrosis scores have been combined with clinical parameters and other novel biomarkers to predict risks of HCC for patients who achieved SVR. These models still need to be validated and standardized prior to applying to routine clinical care.

Citing Articles

Bee Pollen as a Source of Biopharmaceuticals for Neurodegeneration and Cancer Research: A Scoping Review and Translational Prospects.

Kacemi R, Campos M Molecules. 2025; 29(24).

PMID: 39769981 PMC: 11677910. DOI: 10.3390/molecules29245893.

Trends in Hepatocellular Carcinoma Mortality Rates in the US and Projections Through 2040.

Qiu S, Cai J, Yang Z, He X, Xing Z, Zu J JAMA Netw Open. 2024; 7(11):e2445525.

PMID: 39556395 PMC: 11574689. DOI: 10.1001/jamanetworkopen.2024.45525.

Low plasma levels of BTLA and LAG-3 before HCV therapy are associated with metabolic disorders after HCV eradication in persons with HIV/HCV coinfection: a retrospective study.

Martin-Escolano R, Virseda-Berdices A, Berenguer J, Gonzalez-Garcia J, Brochado-Kith O, Fernandez-Rodriguez A Front Pharmacol. 2024; 15:1341612.

PMID: 39530457 PMC: 11551606. DOI: 10.3389/fphar.2024.1341612.

In Vitro and In Vivo Evaluation of Virus-Induced Innate Immunity in Mouse.

Wang Z, Hu P, Shan X, Wang B, Xiong H, Yu Q Methods Mol Biol. 2024; 2854:237-251.

PMID: 39192134 DOI: 10.1007/978-1-0716-4108-8_23.

Association of serum lipid profile with liver fibrosis in HCV‑coinfected HIV patients on suppressive anti‑retroviral therapy.

Srisopa S, Pipatsatitpong D, Akekawatchai C Biomed Rep. 2024; 21(4):146.

PMID: 39170754 PMC: 11337153. DOI: 10.3892/br.2024.1834.

References

Ryder S, Irving W, Jones D, Neal K, Underwood J . Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut. 2004; 53(3):451-5. PMC: 1773967. DOI: 10.1136/gut.2003.021691. View

Balart L, Lisker-Melman M, Hamzeh F, Kwok A, Lentz E, Rodriguez-Torres M . Peginterferon α-2a plus ribavirin in Latino and Non-Latino Whites with HCV genotype 1: Histologic outcomes and tolerability from the LATINO Study. Am J Gastroenterol. 2010; 105(10):2177-85. DOI: 10.1038/ajg.2010.157. View

Grebely J, Prins M, Hellard M, Cox A, Osburn W, Lauer G . Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis. 2012; 12(5):408-14. PMC: 3608418. DOI: 10.1016/S1473-3099(12)70010-5. View

Noureddin M, Wong M, Todo T, Lu S, Sanyal A, Mena E . Fatty liver in hepatitis C patients post-sustained virological response with direct-acting antivirals. World J Gastroenterol. 2018; 24(11):1269-1277. PMC: 5859229. DOI: 10.3748/wjg.v24.i11.1269. View

Lopez-Dieguez M, Montes M, Pascual-Pareja J, Quereda C, von Wichmann M, Berenguer J . The natural history of liver cirrhosis in HIV-hepatitis C virus-coinfected patients. AIDS. 2011; 25(7):899-904. DOI: 10.1097/QAD.0b013e3283454174. View

Caldwell S, Li X, Rourk R, Millar A, Sosnowski K, Sue M . Hepatitis C infection by polymerase chain reaction in alcoholics: false-positive ELISA results and the influence of infection on a clinical prognostic score. Am J Gastroenterol. 1993; 88(7):1016-21. View

Kono M, Nishida N, Hagiwara S, Minami T, Chishina H, Arizumi T . Unique Characteristics Associated with Sustained Liver Damage in Chronic Hepatitis C Patients Treated with Direct Acting Antivirals. Dig Dis. 2017; 35(6):556-564. DOI: 10.1159/000480148. View

Papastergiou V, Tsochatzis E, Burroughs A . Non-invasive assessment of liver fibrosis. Ann Gastroenterol. 2014; 25(3):218-231. PMC: 3959378. View

Hagan H, Jordan A, Neurer J, Cleland C . Incidence of sexually transmitted hepatitis C virus infection in HIV-positive men who have sex with men. AIDS. 2015; 29(17):2335-45. PMC: 4640945. DOI: 10.1097/QAD.0000000000000834. View

10.

Sharma S, Khalili K, Nguyen G . Non-invasive diagnosis of advanced fibrosis and cirrhosis. World J Gastroenterol. 2014; 20(45):16820-30. PMC: 4258552. DOI: 10.3748/wjg.v20.i45.16820. View

11.

Khan M, Saito S, Takagi S, Ohnishi H, Izumi H, Sakauchi F . Relationship between hepatocellular carcinoma and impaired glucose tolerance among Japanese. Hepatogastroenterology. 2006; 53(71):742-6. View

12.

Wei H, Song B . Elastography for Longitudinal Assessment of Liver Fibrosis after Antiviral Therapy: A Review. J Clin Transl Hepatol. 2021; 8(4):445-453. PMC: 7782123. DOI: 10.14218/JCTH.2020.00033. View

13.

. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018; 69(2):461-511. DOI: 10.1016/j.jhep.2018.03.026. View

14.

Cholet F, Nousbaum J, Richecoeur M, Oger E, Cauvin J, Lagarde N . Factors associated with liver steatosis and fibrosis in chronic hepatitis C patients. Gastroenterol Clin Biol. 2004; 28(3):272-8. DOI: 10.1016/s0399-8320(04)94918-4. View

15.

Falade-Nwulia O, Suarez-Cuervo C, Nelson D, Fried M, Segal J, Sulkowski M . Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review. Ann Intern Med. 2017; 166(9):637-648. PMC: 5486987. DOI: 10.7326/M16-2575. View

16.

Allen N, Beral V, Casabonne D, Kan S, Reeves G, Brown A . Moderate alcohol intake and cancer incidence in women. J Natl Cancer Inst. 2009; 101(5):296-305. DOI: 10.1093/jnci/djn514. View

17.

Hoshida Y, Villanueva A, Sangiovanni A, Sole M, Hur C, Andersson K . Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology. 2013; 144(5):1024-30. PMC: 3633736. DOI: 10.1053/j.gastro.2013.01.021. View

18.

Ioannou G, Green P, Beste L, Mun E, Kerr K, Berry K . Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C. J Hepatol. 2018; 69(5):1088-1098. PMC: 6201746. DOI: 10.1016/j.jhep.2018.07.024. View

19.

Mosley J, Operskalski E, Tobler L, Andrews W, Phelps B, Dockter J . Viral and host factors in early hepatitis C virus infection. Hepatology. 2005; 42(1):86-92. DOI: 10.1002/hep.20742. View

20.

Polesel J, Zucchetto A, Montella M, Dal Maso L, Crispo A, La Vecchia C . The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma. Ann Oncol. 2008; 20(2):353-7. DOI: 10.1093/annonc/mdn565. View